Comparison of consensus of Kazakhstan Cancer Society with international guidelines.
| Comparison | Kazakhstan consensus | ESTRO/ASTRO and others [11–14] | Canadian/Chinese guidelines [15, 16] |
|---|---|---|---|
| Scope | Focus exclusively on oligoprogressive disease | Primarily oligometastatic disease; some mention oligoprogression | Primarily oligometastatic disease, occasionally include oligoprogressive disease |
| Definition | Limited progression under systemic control; lesion size/localization not relevant | Limited number of metastases; oligoprogressive disease sometimes acknowledged but not central | Oligometastatic disease defined as ≤ 3–5 lesions; oligoprogressive disease treated as subset |
| Number of lesions | No consensus (≤ 5 vs. any treatable number) | Typically ≤ 3–5 lesions | ≤ 3–5 lesions |
| Diagnosis | CT or PET-CT sufficient; biopsy and molecular testing in selected cases | Imaging standard; biopsy increasingly encouraged | Imaging standard; molecular testing emphasized |
| Treatment | Continue systemic therapy if effective; local therapy prioritized, SBRT/SABR favored | Local therapy + systemic continuation recommended | Local therapy + systemic continuation standard; stricter lesion thresholds |
| Repeat oligo-progression | No consensus (systemic switch vs. continued systemic with local therapy) | Rarely specified | Early systemic switch sometimes favored |
CT: computed tomography scan; PET-CT: positron emission tomography-CT; SBRT: stereotactic body radiation therapy; SABR: stereotactic ablative body radiotherapy.